

Mannheim, February 12, 2019

16. ELN Symposium with 19. KNL Symposium

Congress Center Rosengarten, Mannheim

	Mahler 1	Chairs/Contributors
8:00 - 9:30	Session 1 WP4 CML	F. Guilhot, L. Stenke
15'	Nordic EURO-SKI follow up study. Late losses of MMR	J. Richter
15'	Prognostic model of successful TKI discontinuation based on the RU-SKI prospective study	O. Shukhov
15'	European blast crisis registry	A.-M. Brioli, M. Lauseker
10'	ELN pregnancy database, part 1	E. Abruzzese
10'	part 2	E. Chelysheva
15'	Social parameters are independent predictors for survival in CML	S. Kulikov
9:30 - 9:45	Coffee Break	
9:45 - 11:15	Session 2: WP5 AML	C. Thiede, C. Müller-Tidow
15'	Update MRD following the 2017 recommendation paper	C.Thiede
15'	ELN definition for unfitnes in AML a new initiative	A.Venditti
15'	“Certification” to become an ELN Center	C.Thiede
15'	Immunotherapy task force in AML	A. van de Loosdrecht
10'	Dendritic cell vaccination study in AML (WIDEA study)	Z. Berneman
10'	Dendritic cell vaccination study (DCone Study)	A. van de Loosdrecht
10'	Update ELN recommendations for APL	P. Montesinos
11:15-11:30	Break	
11:30-13:00	Session 3: HARMONY	J. Hernandez
15'	Outcomes definitions: Delphi survey results on HMs and next steps Current status of pilot projects:	L. Bullinger
15'	Results on AML	L. Bullinger
15'	Results on CLL	P. Ghia
15'	Results on MDS	P. Fenaux
	Upcoming projects:	
10'	NHL	M. Dreyling
10'	MM	M. Boccadoro (TBC)
10'	2019 program	J. Hernández, G. Sanz
13:00-14:00	Lunch	

14:00-15:30	Session 4: WP8 MDS/MDS-Right	T. de Witte
2'	Welcome/Introduction Report EUMDS Registry SC meeting	P. Fenaux, T. de Witte
3'	a) General overview EUMDS	A. Smith
3'	b) Planning EUMDS studies	A. Smith
	c) Presentation of selected ongoing studies EUMDS meeting:	
8'	- Non-invasive diagnostic algorithm	M. Mittelman
10'	- Transfusion support in MDS	S. Stanworth
4'	d) Future & logistics EUMDS registry	T. de Witte
7'	Progress of trial platform: EMSCO, (planned) trials	P. Fenaux
10'	Revision IWG 2006 criteria	P. Fenaux, R. Itzykson
7'	FP7: progress of TRIAGE-MDS (Transcan) Horizon 2020: progress MDS-RIGHT	J. Janssen
7'	- Summary of MDS-RIGHT meeting 11.2.2019	T. de Witte
4'	- Core outcome set for MDS - results from a Delphi study	R. Stauder
7'	Report from ELN MDS flow working group	A. van de Loosdrecht
5'	IMI-2: HARMONY - MDS activities	G. Sanz, J. Hernandez
5'	EuroBloodNet	P. Fenaux
8'	New Horizon 2020 application: SMART	T. de Witte
15:30-16:00	Coffee Break	
16:00-17:15	General Assembly and Summary reports	
20'	General Assembly	
5'	WP4	F. Guilhot
5'	WP5	C. Thiede
5'	HARMONY	J. Hernandez
5'	WP8/MDS-RIGHT	T. de Witte
5'	WP6	D. Hoelzer
5'	WP7 (ERIC,CLL)	P. Ghia
5'	WP9	T. Barbui
5'	WP10	M. Bené
5'	WP12 (MRD, NGS)	T. Haferlach
5'	WP14	D. Niederwieser
5'	WP17	M. Pfirrmann
17:15-17:30	Break	
17:30-17:50	ELN Merit Awards	R. Hehlmann
5'		Clara Bloomfield (Introducer H. Doehner)
5'		Angelo Carella (Introducer G. Saglio)
5'		Guido Guidi (Introducer F. Pane)
5'		Richard Silver (Introducer R. Hehlmann)
17:50-19:50	Session 12: Keynote lectures	R. Hehlmann, D. Hoelzer
20'	Global development of BCR-ABL monitoring	N. Cross
20'	Molecular diagnostics in acute leukemias: where is the benefit?	T. Haferlach
20'	Cytogenetics in the diagnosis of leukemia	C. Haferlach
20'	What can tumor cytogenetics contribute to our understanding of carcinogenesis?	C. Mecucci
20'	Molecular diagnostics in polycythemia vera, essential thrombocythemia and primary myelofibrosis	W. Vainchenker
20'	The AGIMM project: an up-to-date journey through myeloproliferative neoplasms	A. Vannucchi

20:00	Working dinner in the foyer	
	Mahler 2	Chairs/Contributors
8:00 - 9:30	Session 5: WP6 ALL Outcome of patients with Ph+ ALL in first molecular vs. overt relapse included in the trial ALL PH08 from the PETHEMA Group Chemofree approach with blinatumomab + dasatinib on Ph+ ALL EWALL PH01 (dasatinib in elderly ALL) EWALL PH02 (nilotinib in elderly ALL study report and the upcoming randomized EWALL-PH03, ponatinib, blinatumomab) Minor-BCR-RV by Ph+ALL, GMALL Ph-like ALL in the GIMEMA 1913	D. Hoelzer J. Ribera S. Chiaretti P. Rousselot O. Ottmann H. Pfeifer S. Chiaretti
9:30- 9:45	Coffee Break	
9:45-11:15	Session 6: WP7 CLL 15' Welcome and Introduction Updates on ongoing projects: 10' BR in treatment naïve patients with CLL outside clinical trials 10' Immunogenetics and stereotypy project 10' Prevalence of BTK and PLCγ2 mutations in patients relapsing under ibrutinib 10' Update on the gene mutation project 10' ERIC study on prognostic and predictive impact of minor TP53 variants – update 10' ERIC TP53 certification - results of round 7 10' ERIC IG Certification - Results of Round 4 5' Final remarks	P. Ghia P. Ghia A. Cuneo A. Agathangelidis L. Scarfò, L. Sutton L. Sutton S. Pospisilova S. Pavlova A. Agathangelidis P. Ghia
11:15-11:30	Break	
11:30-13:00	Session 7: WP9 MPN A: Consensus statement by the European Leukemia Net on “Unmet Clinical Needs of Management of Thrombosis in Myeloproliferative Neoplasms” 10' Presentation of the project 10' Providing evidence on benefits and risks of cytoreduction in patients with SVT without hypercythemia 10' Improving the grading system of the risk of thrombosis in PV 10' Improving the knowledge on the association between somatic mutations and risk factors for thrombosis in MPNs 20' Discussion 15' General discussion B: New project 10' Pulmonary hypertension in MPN	T. Barbui, J.-J. Kiladjian G. Barosi J.-J. Kiladjian T. Barbui A. Vannucchi A. Reiter, S. Koschmieder, M. Griesshammer J.-M. Scandura
13:00-14:00	Lunch	
14:00-15:30	Session 8: WP10 Immunophenotyping 30' Update on the morphology faculty 10' Discussion 30' New unsupervised strategies for flow cytometry analysis 10' Discussion 10' Any other issue	M. Bené, G. Zini G. Zini M. Bené

Mahler 3**Chairs/Contributors****8:00 - 9:30****Session 9: WP12/13 MRD/NGS**

- 20' NGS for MRD
- 20' Ring trials on NPM1 and FLT3
- 20' WGS and RNA-Seq
- 20' News in CLL, and HARMONY for WP12/13
- 10' Future steps in WP 12 and WP13

T. Haferlach, C. Thiede, N. Cross

M. Heuser
 C. Thiede
 T. Haferlach
 J. Hernandez
 All

9:30 - 9:45

Coffee Break

9:45 - 11:15**Session 10: WP14 Transplantation**

- 15' Treosulfan conditioning for allo transplantation in Multiple Myeloma - reduced nonrelapse mortality and improved overall survival in the upfront tandem auto/allo approach. A retrospective registry analysis by the EBMT
- 15' Virus-specific T-Cells for treatment of virus infection after SCT (state of the art and protocol presentation)
- 15' MSC for GvHD (European Rethrim Study)
- 15' Gene therapy studies (Thalassemia; ALD;)
- 15' Telemedicine on global level
- 15' Randomized HSCT study in elderly patients with AML in CR1 and MUD or MRD

D. Niederwieser, J. Apperley

G. Gahrton
 T. Feuchtinger
 D. Niederwieser, W. Fibbe
 Köhl, D. Niederwieser, Gorbacioglu
 D. Niederwieser
 D. Niederwieser, Y. Chalandon, M. Stelljes

13:00-14:00**Lunch****14:00-15:30****Session 11: WP17 Biometry**

- 5' Words of welcome
- 25' Bayesian statistics and trial designs in leukemias: past, present, future
- 25' Interpretation of prognostic model results - patient data and outcome probabilities
- 25' Novel insights in survival analysis - dealing with particular causes of death
- 10' Summary and future

M. Pfirrmann, J. Guilhot, M. Lauseker

M. Pfirrmann
 Joëlle Guilhot
 M. Pfirrmann
 M. Lauseker
 All

